Alopecia Areata Epidemiology Forecast

Key Highlights

• A complicated, polygenic, autoimmune condition called alopecia areata causes non-scarring patches on the scalp and body hair, which can be emotionally distressing. Clinically diverse, alopecia areata has an erratic course, with 80% of patients seeing spontaneous hair growth within the first year and the possibility of rapid recurrence at any time. Instances that start in childhood are more severe than instances that start as adults.
• Usually, the pattern of hair loss and the patient's medical history can be used to diagnose alopecia areata. To confirm the diagnosis, a biopsy may be required in some circumstances. Dermoscopy (trichoscopy) has recently become a useful auxiliary tool. Dermoscopic observations that indicate early regrowth include yellow and black spots, broken hairs, exclamation point hairs, and short vellus hairs.
• There are different types of alopecia areata, among which the three main forms include: alopecia areata patchy, alopecia totalis, and alopecia universalis.
• Alopecia areata is typically diagnosed on clinical features; however, additional tests like trichoscopy, hair pull test, and skin biopsy may aid in diagnosis.
• As per the research by National Alopecia Areata Foundation (NAAF), alopecia areata affects 1 in every 500–1,000 people in the United States. It is one of many recognized forms of alopecia and alopecia areata is the second most common form after androgenetic alopecia.
• As per DelveInsight’s analysis, in the year 2022, the total prevalent cases of alopecia areata were ~1,485,000 cases in the 7MM, which are expected to increase by 2032.
• Among the 7MM, the US accounted for the highest number of prevalent cases in 2022 with ~704,000 cases, which are estimated to increase by the year 2032.
• Therapy efficacy is difficult to estimate due to the unpredictable course of the disease, and spontaneous remission is often observed within the first year. The current therapies focus on immunosuppression that does not influence the long-term course of the disease, creating an unmet need for novel therapies.

Report Summary

DelveInsight’s “Alopecia Areata – Epidemiology Forecast – 2032” report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.

The table given below further depicts the key segments provided in the report:

Alopecia Areata Disease Understanding

Alopecia Areata Overview

People of all ages, both sexes, and all ethnic groups can develop alopecia areata, a common autoimmune skin condition that causes hair loss on the scalp, face, and occasionally other regions of the body.

Over time, there has been significant drift in the etiology of alopecia areata, and several research have proposed various etiologies for the disorder. Most alopecia areata research makes a compelling argument for the involvement of genetic, autoimmune, and environmental variables in the etiology.

Alopecia Areata Diagnosis

An extensive medical and family history should be obtained from an alopecia areata patient, and their entire body, including their nails, should be thoroughly examined. A hair pull test and dermatoscopy should always be added to this. Additional tests, such as a scalp biopsy, a fungal culture, or serology for other autoimmune illnesses or infectious diseases (like syphilis), may be required when clinical findings do not allow for a certain diagnosis.

Further details related to country-based variations are provided in the report…

Alopecia Areata Epidemiology

As the market is derived using a patient-based model, the alopecia areata disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Alopecia Areata, Total Diagnosed Cases of Alopecia Areata, Type-Specific Cases of Alopecia Areata, Cases of Alopecia Areata Based on Age of Onset, Severity-Specific Cases of Alopecia Areata, and Comorbidities Associated With Alopecia Areata in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In 2022, the total prevalent cases of alopecia areata in the United States were approximately 704,000 cases which is projected to increase during the forecast period (2023–2032).
• The total prevalent cases of alopecia areata in EU4 and the UK were approximately 447,000 in 2022. The cases are projected to increase during the forecast period (2023–2032).
• The total prevalent population of alopecia areata in Japan were approximately 334,000 cases in 2022.
• In 2022, for severity specific cases, ~10% of the patient share were estimated for the mild, ~60% moderate, and ~30% cases for severe in the US.

Alopecia Areata Report Insights

• Patient Population
• Total prevalent cases of alopecia areata, total diagnosed cases of alopecia areata, type-specific cases of alopecia areata, cases of alopecia areata based on age of onset, severity-specific cases of alopecia areata, and comorbidities associated with alopecia areata in the 7MM
• Country-wise Epidemiology Distribution

Alopecia Areata Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Alopecia areata Epidemiology Segmentation

Alopecia Areata Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights

• What diseases, costs, and unmet needs are associated with alopecia areata? What will the patient population for alopecia areata patients' growth possibilities be across the 7MM?
• What is the historical and projected patient population for alopecia areata in the US, the EU4 (Germany, France, Italy, Spain), the UK, and Japan?
• What factors will have an impact on the rise in alopecia areata diagnosis?

Reasons to buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in alopecia areata cases in varying geographies over the coming years.
• Detailed overview on type-specific cases of alopecia areata, cases of alopecia areata based on age of onset, severity-specific cases of alopecia areata, and comorbidities associated with alopecia areata in the 7MM is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.